Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm

Author:

Sugarman Ryan,Betts Keith A.,Nie Xiaoyu,Hartman John,Nguyen Hiep

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference7 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA: Cancer J Clin,2021

2. Highlights of Prescribing Information: Opdivo (nivolumab) [US Food and Drug Administration website]. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/225554s112lbl.pdf. Accessed April 15, 2022.

3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021

4. Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions;Nguyen;Explor Res Clin Soc Pharm,2021

5. Confidence intervals for the number needed to treat;Altman;BMJ (Clin Res Ed),1998

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3